Lactobacillus paracasei strain GM-080 for treating allergy related diseases

Abstract

The present invention provides an isolated microorganism strain, Lactobacillus paracasei GM-080, which is found to be effective in treating allergy. The use of the Lactobacillus paracasei GM-080 in treating allergy related disease is also provided.

1. A biologically pure microorganism,  Lactobacillus paracasei  GM-080, deposited at the China Center for Type Culture Collection under CCTCC No.: CCTCC M 204012. 
     
     
       2. A composition comprising the biologically pure microorganism according to  claim 1  and a medium. 
     
     
       3. The biologically pure microorganism according to  claim 1 , wherein the microorganism is live. 
     
     
       4. The biologically pure microorganism according to  claim 1 , wherein the microorganism is inactivated. 
     
     
       5. The biologically pure microorganism according to  claim 1  which is in a pharmaceutical composition, dietary supplement, food, or a component thereof. 
     
     
       6. An in vitro culture comprising  Lactobacillus paracasei  GM-080, deposited at the China Center for Type Culture Collection under CCTCC No.: CCTCC M 204012. 
     
     
       7. An in vitro culture comprising  Lactobacillus paracasei  GM-080, deposited at the China Center for Type Culture Collection under CCTCC No.: CCTCC M 204012 and one or more cells selected from the group consisting of spelenocytes and peripheral blood mononuclear cells. 
     
     
       8. A method for treating an allergy related disease in a subject comprising administering to said subject a composition comprising the biologically pure microorganism according to  claim 1 . 
     
     
       9. The method according to  claim 8 , wherein the allergy related disease is eczema. 
     
     
       10. The method according to  claim 8 , wherein the allergy related disease is atopic dermatitis. 
     
     
       11. The method according to  claim 8 , wherein the allergy related disease is allergic conjunctivitis. 
     
     
       12. The method according to  claim 8 , wherein the allergy related disease is asthma. 
     
     
       13. The method according to  claim 8 , wherein the allergy related disease is rhinitis. 
     
     
       14. The method according to  claim 8 , wherein the allergy related disease is selected from the group consisting of airway hyperreactivity and inflammation, atopic dermatitis, allergic conjunctivitis, rhinitis, sinusitis, hypersensitive pneumonia, extrinsic allergic alveolitis, urticaria, eczema, anaphylaxis, angioedema, allergic and migraine headache, certain gastrointestinal disorders, and asthma. 
     
     
       15. The method according to  claim 14 , wherein the allergy related disease is airway hyperreactivity or inflammation. 
     
     
       16. The method according to  claim 8 , wherein the allergy related disease is associated with exposure to aeroallergen. 
     
     
       17. The method according to  claim 8 , wherein the microorganism is live. 
     
     
       18. The method according to  claim 8 , wherein the microorganism is inactivated. 
     
     
       19. A method for stimulating IFN-γ secretion in a subject comprising administering to said subject a composition comprising the biologically pure microorganism according to  claim 1 . 
     
     
       20. The method according to  claim 19 , wherein the microorganism is live. 
     
     
       21. The method according to  claim 19 , wherein the microorganism is inactivated.